Daily Cosmetic Research Analysis
Analyzed 38 papers and selected 3 impactful papers.
Summary
Analyzed 38 papers and selected 3 impactful articles.
Selected Articles
1. CRISPR-engineered zebrafish expression system for human type III collagen: Therapeutic efficacy in wound healing.
A CRISPR/Cas9-engineered zebrafish line expressing human Col3a1 yielded a collagen composite with intact fibrillar architecture and high thermal stability (71.3 °C). The material reduced inflammatory cytokines, enhanced fibroblast proliferation, and achieved >95% wound closure by day 15 in mice with improved histological regeneration.
Impact: This study introduces a scalable bioengineering platform to produce functional human type III collagen with superior stability and demonstrable preclinical efficacy, addressing key limitations of existing collagen sources.
Clinical Implications: Provides a promising collagen source for future wound dressings and anti-aging dermatologic applications; human safety, immunogenicity, and comparative effectiveness versus bovine/porcine or recombinant yeast/bacterial collagens require clinical validation.
Key Findings
- CRISPR/Cas9 integration of human Col3a1 in zebrafish enabled high-yield collagen extraction (total yield 45.76%).
- Collagen composite showed intact fibrillar structure with high thermal shrinkage temperature (71.3 °C).
- In vitro, the material reduced LPS-induced Tnfα, Il1b, Il6 and increased Il10, while promoting fibroblast proliferation.
- In a murine acute wound model, dressings achieved >95% wound closure within 15 days with improved neoskin thickness and collagen deposition.
Methodological Strengths
- Multiscale validation including structural, cellular (anti-inflammatory, proliferative), and in vivo wound-healing endpoints.
- Quantitative biophysical characterization (thermal shrinkage temperature) and defined genetic integration site.
Limitations
- Preclinical study without human clinical data; immunogenicity and long-term safety are unknown.
- Translational scalability and regulatory manufacturing (GMP) considerations remain to be addressed.
Future Directions: Head-to-head preclinical comparisons with existing collagen sources, GLP toxicology, and phase I/II trials in wound care and aesthetic indications; process optimization for GMP-compliant production.
Human type III collagen (Col III) is a critical component for skin tissue repair and anti-aging, yet its heterologous expression often faces challenges such as incomplete structure and poor thermostability. Here, we established a transgenic zebrafish expression system via CRISPR/Cas9 technology, integrating the human Col3a1 gene into a non-functional region of zebrafish chromosome 4. The extraction yield of total zebrafish collagen (Col III-TC), a composite material comprising both recombinant human Col III and endogenous zebrafish collagens, was 45.76%. Structural analysis revealed intact fibrous architecture and a thermal shrinkage temperature of 71.3 °C, significantly superior to conventional systems. Functionally, Col III-TC exhibited remarkable free radical-scavenging capacity and suppressed LPS-induced inflammation in 3T3-L1 cells (downregulating Tnfα, Il1b, and Il6, while upregulating Il10), alongside promoting fibroblast proliferation. In a murine acute wound model, Col III-TC-based dressings achieved outstanding healing efficacy (>95% closure within 15 days), with histological analysis showing improved neoskin thickness and collagen deposition. The Col3a1 transgenic zebrafish system developed in this study not only provides a novel strategy for heterologous expression of fully functional human proteins, but also highlights the broad application potential of its high-yield collagen in biomedical fields, particularly in wound healing and anti-aging therapies.
2. The Role of Dermoscopy in Optimising Surgical Margins for Keratinocyte Cancers: Updated Evidence from a Systematic Review and Meta-Analysis.
This PRISMA-compliant update shows that dermoscopy-guided excision of keratinocyte cancers significantly reduces incomplete excisions (pooled OR 0.30) and may allow narrower margins without compromising recurrence. Evidence is limited by the observational design and moderate-to-serious risk of bias, warranting high-quality trials.
Impact: Supports an accessible, noninvasive tool to improve surgical precision and cosmetic outcomes in common skin cancers, aligning with evolving guideline recommendations.
Clinical Implications: In settings without Mohs surgery access, preoperative dermoscopic margin mapping may reduce re-excisions and enable tissue-sparing excisions, improving oncological and cosmetic outcomes; standardized protocols and RCTs are needed before guideline integration.
Key Findings
- Ten studies (1,151 patients; 1,186 lesions) included; most addressed basal cell carcinoma with limited SCC data.
- Dermoscopy reduced incomplete excisions (pooled OR 0.30, 95% CI 0.27–0.34; I²=0%).
- Narrower surgical margins were often achievable without increased recurrence.
- All studies were observational with moderate-to-serious risk of bias (ROBINS-I).
Methodological Strengths
- Systematic review and meta-analysis conducted per PRISMA with ROBINS-I risk-of-bias assessment.
- Consistent effect size with low heterogeneity (I²=0%).
Limitations
- All included studies were observational with moderate-to-serious risk of bias.
- Limited data for squamous cell carcinoma; review update was not newly registered.
Future Directions: Conduct randomized or well-controlled prospective trials comparing dermoscopy-guided mapping to standard care and Mohs, with standardized protocols and recurrence/cost-effectiveness endpoints.
BACKGROUND: Keratinocyte cancer (KC) is the most common malignancy worldwide. Surgical excision is the primary treatment, with clear margin delineation critical for oncological and cosmetic outcomes. Dermoscopy, well-established for diagnosis, has recently been included in updated British guidelines as an alternative method for surgical margin planning and may offer improved border visualisation. OBJECTIVES: To update the existing evidence on dermoscopy-guided excision of KC, focusing on margin control and recurrence risk and incorporating newly published studies and re-evaluating its use considering evolving guideline recommendations. METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, EMBASE, and CENTRAL were searched to October 2024. Eligible studies compared dermoscopy-guided with conventional surgical excision of histologically confirmed KC. The primary outcome was incomplete excision rate. Risk of bias was assessed using ROBINS-I, and meta-analysis conducted using a DerSimonian-Laird random-effects model. RESULTS: Ten studies (1,151 patients; 1,186 lesions) were included; four contributed to meta-analysis. Most focused on BCC; SCC data were limited. Dermoscopy was associated with improved surgical precision and reduced incomplete excision (pooled OR: 0.30, 95% CI: 0.27-0.34; I² = 0%, P = 0.99), although all studies were observational and at moderate to serious risk of bias. Narrower margins were often achieved without compromising recurrence outcomes. CONCLUSIONS: Dermoscopy may enhance preoperative planning in KC excision, but evidence remains limited by methodological constraints. These findings support further high-quality trials to confirm clinical utility and define its role in future surgical guidelines. REGISTRATION: This updated Systematic Review and Meta Analysis was not registered in PROSPERO nor was a new protocol created, as it is an update of a previously registered review (ID: CRD42021243270).
3. Nontarget screening and suspect identification of organic chlorinated compounds in cosmetics and personal care products using UHPLC-Q-Orbitrap-HRMS.
An isotope-pattern–driven UHPLC-Q-Orbitrap-HRMS workflow identified 227 chlorinated compounds in children's skincare, including banned agents such as triclosan. Predominant classes were heterocyclics and ethers; chlorhexidine reached 0.456%, underscoring regulatory gaps and pediatric exposure risks.
Impact: Provides a scalable, validated non-target framework for uncovering concealed or banned chlorinated chemicals in CPCPs, directly informing regulatory surveillance and consumer safety.
Clinical Implications: Clinicians should be aware of potential chlorinated compound exposure from cosmetics, particularly in children; findings support stricter enforcement, transparent labeling, and reformulation to reduce irritancy, endocrine disruption, and sensitization risks.
Key Findings
- Developed an integrated isotope-pattern nontarget screening and suspect identification framework using UHPLC-Q-Orbitrap-HRMS.
- Identified 227 chlorinated compounds in children's skincare (3 CL1, 9 CL2, 93 CL3, 122 CL4; masses 128–931 Da; RDBE 0–29).
- Heterocyclics and ethers predominated among higher-confidence identifications.
- Detected banned or restricted agents (e.g., triclosan, elubiol, 4-chloroaniline); chlorhexidine quantified up to 0.456%.
Methodological Strengths
- High-resolution accurate-mass platform with isotope pattern recognition enabling broad, unbiased detection.
- Combined nontarget and suspect pipelines validated on real-world children's skincare products.
Limitations
- Many identifications were tentative (CL3–CL4) without confirmatory standards.
- Sampling frame and number of products were not specified; exposure and health effect quantification were not assessed.
Future Directions: Expand sampling across regions and product categories, incorporate targeted quantification for priority chemicals, and link to biomonitoring for risk assessment.
Organic chlorinated compounds have been extensively incorporated into cosmetics and personal care products (CPCPs) as germicides, surfactants, and oil-controlling agents, leading to potential human exposure and associated health risks. However, available research has mostly been limited to several chlorinated compounds in CPCPs, e.g., triclosan and triclocarban. In this study, an integrated analytical framework was established combining isotope-pattern-based nontarget screening with database-assisted suspect identification to comprehensively characterize organic chlorinated compounds in CPCPs. The framework was successfully validated by screening and identification of chlorinated compounds in children's skincare products for sale in China. A total of 227 chlorinated compounds were tentatively identified, including 3 confidence level (CL)1, 9 CL2, 93 CL3, and 122 CL4 compounds with RDBE values of 0 - 29 and molecular masses of 128 - 931 Da. Heterocyclics and ethers were predominant among the CL1-CL3 compounds. Chlorhexidine was quantified maximally at 0.456 %. Triclosan, elubiol, and 4-chloroaniline were also detected in at least one product although they have been banned in skincare products. Overall, the results demonstrated robustness of the comprehensive analytical framework in identifying and characterizing chlorinated compounds in CPCPs. In addition, this research shed light on potential exposure of young children to a cocktail of chlorinated compounds, underscoring urgent need for strict regulations of chemical addition and transparent ingredient labeling to ensure safe use of CPCPs.